- Home
- SPRY vs IDYA Comparison
SPRY vs IDYA Comparison
Compare SPRY & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRY
- IDYA
- Stock Information
- Founded
- SPRY 2015
- IDYA 2015
- Country
- SPRY United States
- IDYA United States
- Employees
- SPRY N/A
- IDYA N/A
- Industry
- SPRY Biotechnology: Pharmaceutical Preparations
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- SPRY Health Care
- IDYA Health Care
- Exchange
- SPRY Nasdaq
- IDYA Nasdaq
- Market Cap
- SPRY 1.4B
- IDYA 1.5B
- IPO Year
- SPRY N/A
- IDYA 2019
- Fundamental
- Price
- SPRY $14.16
- IDYA $20.58
- Analyst Decision
- SPRY Strong Buy
- IDYA Strong Buy
- Analyst Count
- SPRY 4
- IDYA 12
- Target Price
- SPRY $28.75
- IDYA $54.27
- AVG Volume (30 Days)
- SPRY 1.5M
- IDYA 1.5M
- Earning Date
- SPRY 05-14-2025
- IDYA 05-06-2025
- Dividend Yield
- SPRY N/A
- IDYA N/A
- EPS Growth
- SPRY N/A
- IDYA N/A
- EPS
- SPRY N/A
- IDYA N/A
- Revenue
- SPRY $97,122,000.00
- IDYA $7,000,000.00
- Revenue This Year
- SPRY $1.49
- IDYA $68.39
- Revenue Next Year
- SPRY $141.68
- IDYA $324.54
- P/E Ratio
- SPRY N/A
- IDYA N/A
- Revenue Growth
- SPRY 971120.00
- IDYA N/A
- 52 Week Low
- SPRY $7.55
- IDYA $13.45
- 52 Week High
- SPRY $18.51
- IDYA $44.42
- Technical
- Relative Strength Index (RSI)
- SPRY 50.86
- IDYA 62.40
- Support Level
- SPRY $14.32
- IDYA $19.26
- Resistance Level
- SPRY $15.50
- IDYA $20.46
- Average True Range (ATR)
- SPRY 0.84
- IDYA 0.98
- MACD
- SPRY 0.06
- IDYA 0.20
- Stochastic Oscillator
- SPRY 65.19
- IDYA 95.28
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.